McAdam LLC’s PAVmed PAVM Stock Holding History

McAdam LLC’s Portfolio PAVM Stock Details PAVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-32	Closed	-$4.3K	–	284
2023 Q3	$4.3K	Sell	32 -5	-14%	-$775	﹤0.01%	259
2023 Q2	$6.85K	Buy	37 +6	+19%	+$1.2K	﹤0.01%	262
2023 Q1	$5.15K	Buy	+31	New	+$6.53K	﹤0.01%	254

Other funds holding PAVM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

XML Financial Bethesda, Maryland $1.24B AUM 20.4% 1-Year Est. Return

McAdam LLC's PAVM Position: Q4 2023 in Review

McAdam LLC sold out of PAVmed (PAVM) in Q4 2023, closing a stake of 32 shares — an estimated $4.3K sold.

McAdam LLC first reported a position in PAVM in Q1 2023 and held it in 3 quarters. The position peaked at $6.85K in Q2 2023. 23 funds tracked by Wall St. Rank hold PAVM as of Q4 2023.

McAdam LLC reported no remaining PAVmed position as of Q4 2023 after selling out during the quarter.
McAdam LLC sold 32 PAVmed shares in Q4 2023, an estimated $4.3K.
McAdam LLC first reported a position in PAVmed in Q1 2023 and held it in 3 quarters.
McAdam LLC's PAVmed position peaked at $6.85K in Q2 2023.
23 funds tracked by Wall St. Rank held PAVmed as of Q4 2023.

Based on McAdam LLC's 13F filing for Q4 2023, filed 5 Feb 2024.